We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

By LabMedica International staff writers
Posted on 17 May 2022

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). More...

Identifying blood-based signatures of brain health and preclinical pathology may offer insights into early disease mechanisms and highlight avenues for intervention.

Previous studies have identified associations between several metabolite classes and imaging markers related to neurodegeneration, including particular lipids and amino acids. Blood metabolites may also present as potential candidates for these associations. Due to their proximity to core biological processes, they are uniquely placed to capture real-time physiological changes and may allow insights into the processes associated with emergence of disease.

A team of medical scientists led by the University College London group (London UK) enrolled at age 69-71, 502 participants in Insight 46, the neuroscience sub-study. Accompanying MRI and amyloid-PET imaging data were present for 437 participants. Blood samples were collected by trained research nurses. Samples were stored at - 80⁰ C. Following quality control, concentrations of 1,019 metabolites, detected with liquid chromatography-mass spectrometry, were available for 1,740 participants at age 60-64.

The scientists used Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS), concentrations of 1,401 metabolites were detected and measured by Metabolon Inc (Durham, NC, USA) among participants. Metabolites were assigned to nine families (lipids, amino acids, xenobiotics, peptides, nucleotides, cofactors and vitamins, carbohydrates, energy and partially characterized molecules) and further organized into pathways. Unknown metabolites were assigned to an “Unknown” family and pathway and denoted by a number prefixed by an “X”; these were included in all analyses.

The investigators reported that in the fully adjusted model, three lipid modules were associated with a brain volume measure: one enriched in sphingolipids, one in several fatty acid pathways, and another in diacylglycerols and phosphatidylethanolamines. Twenty-two hub metabolites were associated with an imaging outcome. Some nominal associations were reported for amyloid-β, and with an AD PRS in the genetic analysis, but none survived multiple testing corrections.

The authors concluded that their findings highlight relationships between groups of lipids and structural brain measures, as well as key metabolites within these that are likely to be driving associations. Future work should be directed towards understanding if these metabolites associate with longitudinal changes in brain volumes, and whether relationships are causal; this could advance our understanding of brain health and neurodegeneration, and reveal possible targets of intervention. The study was pre-published on April 29, 2022 in the journal medRxiv.

Related Links:
University College London 
Metabolon Inc 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.